Ginsenoside Rg1 impairs homologous recombination repair by targeting CtBP-interacting protein and sensitizes hepatoblastoma cells to DNA damage
- 1 September 2018
- journal article
- research article
- Published by Wolters Kluwer Health in Anti-Cancer Drugs
- Vol. 29 (8) , 756-766
Abstract
The ginsenoside Rg1, the primary pharmacologically active ingredient of the traditional Chinese herb ginseng, is widely used in the clinical treatment of diseases of the immune and nervous systems. Recent studies have shown that it also has an antitumor effect. In this study, we explored the effects of Rg1 on hepatoblastoma (HB) and its underlying mechanisms. We demonstrated that Rg1 significantly inhibited HB cell growth both in vivo and in vitro. Mechanistic studies revealed that Rg1 impaired homologous recombination and triggered double-strand breaks in HB cells by directly targeting CtBP-interacting protein (CtIP), a key double-strand break repair factor, which is highly expressed in HB tissues. Moreover, we also demonstrated that Rg1 sensitized HB cells to DNA-damaging agents both in vitro and in vivo. In conclusion, our data not only demonstrate the potential clinical application of Rg1 as a novel chemotherapeutic candidate but also offer a mechanism-based therapeutic option by which DNA-damaging agents can be used in combination with Rg1 to target HB.Keywords
This publication has 52 references indexed in Scilit:
- Unresectable hepatoblastoma: current perspectivesHepatic Medicine: Evidence and Research, 2017
- Pediatric liver transplantation for hepatoblastomaTranslational Gastroenterology and Hepatology, 2016
- Hepatoblastoma state of the artCurrent Opinion in Pediatrics, 2014
- Predictors of survival and incidence of hepatoblastoma in the paediatric populationHPB, 2013
- Current and Future Management Strategies for Relapsed or Progressive HepatoblastomaPediatric Drugs, 2012
- Pathology: A pictorial review. A selected atlas of paediatric liver pathologyClinics and Research in Hepatology and Gastroenterology, 2012
- Cisplatin versus Cisplatin plus Doxorubicin for Standard-Risk HepatoblastomaNew England Journal of Medicine, 2009
- The current management of hepatoblastoma: A combination of chemotherapy, conventional resection, and liver transplantationThe Journal of Pediatrics, 2005
- Cisplatin, Doxorubicin, and Delayed Surgery for Childhood Hepatoblastoma: A Successful Approach—Results of the First Prospective Study of the International Society of Pediatric OncologyJournal of Clinical Oncology, 2000
- Liver tumoursEuropean Journal of Cancer, 1999